Login to Your Account



Clinic Roundup


Thursday, September 29, 2011
SanBio Inc., of Mountain View, Calif., reported that the first subject in a Phase I/IIa trial has been treated with SB623. The two-site study will evaluate 18 patients who have suffered an ischemic stroke within the past six to 24 months and have a motor neurological deficit.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription